HUTCHMED (China) Limited (HCM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

HCM scores 42 out of 100, grade D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: the Fundamental Cash Engine scores 4/20 (ROIC -2.5%; FCF yield -3.32%), which is the weakest pillar and reflects value destruction and negative free cash flow. Whale 13F Flow scores 9/20 and Insider Conviction scores 7/20, indicating weak smart-money and insider support in the source data. Macro Regime Fit scores 10/20 with a beta of 1.0 and sector sensitivity noted. Forensic Balance Sheet scores 12/20, drawing on an Altman Z of 3.63, a Piotroski F of 4/9, and a debt-to-equity of 0.06; this is the strongest pillar, indicating the balance sheet is less distressed than the cash flow and flow signals. For a prospective investor, the implication is that the low headline P/E of 5. The balance-sheet pillar offers some downside cushion, but the rating as a whole points to caution rather than conviction.

HUTCHMED (China) Limited trades on NASDAQ under HCM and is classified in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry, per the SEC profile. The company reported revenue of $548.5M for FY 2025, indicating a commercial operation generating sales. Specific details on how it monetizes its products are —

Revenue declined from $838.0M (FY 2023) to $630.2M (FY 2024) and $548.5M (FY 2025), while operating income turned negative in both FY 2024 and FY 2025. FY 2025 net income of $456.9M sits far above operating income of -$39. And market data, ROIC is -2.5%, the operating margin is -7.1%, and the gross margin is listed as 0%. The Altman Z-Score is 3.63 and the Piotroski F-Score is 4/9, while the debt-to-equity ratio is 0.06; FY 2025 cash of $71.3M against debt of $68.2M is consistent with a modest, but declining, cash position.

• 🐂 Primary Bull Case: A reported GSK deal with up to $1.185B in potential milestones could strengthen the cash engine that currently scores 4/20. With Fundamental Cash Engine at 4/20 (ROIC -2.5%, FCF yield -3.32%) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $9.77 – $16.33 52-week range.
• 🐻 Primary Bear Case: ROIC of -2.5% and FCF yield of -3.32% show the business is not currently converting its reported earnings into cash. Investors must weigh 5.2x trailing P/E against -7.1% operating margins and a 1.00 macro beta if sector demand softens.

Upstream and downstream dependencies: — Sector correlations: — The one ripple the source data supports is the GSK licensing deal, which, per the news feed, carries up to $1.185B in potential milestones; that is a contractual pipeline item and a second-order factor for investors to track, since milestone receipt would flow into the cash engine that the RQD rating currently scores at 4/20. Bottlenecks: —

• Key Question #1: What drives the gap between FY 2025 net income of $456.9M and operating income of -$39.2M, and is the net income recurring?
• Key Question #2: What is the timing and probability of the GSK milestone payments up to $1.185B, and how do they change the FCF trajectory?
• Key Question #3: What are HCM's product lines, revenue mix, and customer concentration?